Market Risers: KEFI Minerals plc, GlaxoSmithKline plc, AstraZeneca plc, Centrica PLC, Burberry Group plc & Associated British Foods plc

KEFI Minerals
[shareaholic app="share_buttons" id_name="post_below_content"]

The share price for KEFI Minerals plc ticker lookup code: LON:KEFI has gained 4.43% or 0.07 points throughout today’s trading session so far. Investors seem confident throughout the session. The periods high has reached 1.75 dropping as low as 1.58. Volume total for shares traded during this period was 2,168,087 whilst the average number of shares exchanged is 5,495,104. A 52 week share price high is 5 about 3.42 points in difference to the previous days close of business and a 52 week low sitting at 1.38 making a difference of 0.2 points. KEFI Minerals plc now has a 20 moving average of 1.74 with a 50 day SMA of 1.98. The market capitalisation currently stands at £9.30m at the time of this report. The stock is traded in GBX. Mcap is measured in GBP. This article was written with the last trade for KEFI Minerals plc being recorded at Wednesday, November 7, 2018 at 11:21:33 AM GMT with the stock price trading at 1.65 GBX.

 

The trading price for GlaxoSmithKline plc company symbol: LON:GSK has gained 1.22% or 18.38 points in today’s trading session so far. Buyers have remained optimistic throughout the session. Range high for the period so far is 1523.8 meanwhile the session low reached 1501.8. The total volume of shares exchanged through this period comes to 1,363,192 while the average shares exchanged is 9,788,202. The 52 week high for the share price is 1631.13 some 128.73 points difference from the previous close and the 52 week low at 1179.39 which is a variance of 323.01 points. GlaxoSmithKline plc now has a 20 simple moving average of 1524.92 and also a 50 day MA at 1532.97. The market capitalisation is now £75,439.15m at the time of this report. The share price is in Great British pence. Mcap is measured in GBP. This article was written with the last trade for GlaxoSmithKline plc being recorded at Wednesday, November 7, 2018 at 12:06:16 PM GMT with the stock price trading at 1520.78 GBX.

 

Shares of AstraZeneca plc ticker code: LON:AZN has climbed 1.25% or 72 points during today’s session so far. Buyers seem confident during the trading session. The periods high has reached 5867 dipping to 5749. Volume total for shares traded at this point reached 418,182 while the daily average number of shares exchanged is 2,459,750. The 52 week high for the share price is 6126.4 amounting to 368.4 points difference from the previous days close and putting the 52 week low at 4544.5 making a difference of 1213.5 points. AstraZeneca plc now has a 20 SMA at 58.81 and also a 50 day simple moving average now of 58.48. This puts the market capitalisation now at £73,532.67m at the time of this report. The share price is in GBX. Mcap is measured in GBP. This article was written with the last trade for AstraZeneca plc being recorded at Wednesday, November 7, 2018 at 12:06:15 PM GMT with the stock price trading at 5830 GBX.

 

Shares in Centrica PLC ticker code: LON:CNA has increased 2.21% or 3.3 points in today’s trading session so far. Investors have so far held a positive outlook throughout the session. The period high has peaked at 152.93 dipping to 149.58. The amount of shares exchanged has so far reached 7,422,468 with the average number of shares traded daily being 28,326,316. A 52 week high for the stock is 173.3 which is 24 points in difference on the previous days close and a 52 week low being 123.1 which is a variance of 26.2 points. Centrica PLC has a 20 SMA of 149.21 and now a 50 day MA at 149.68. This puts the market capitalisation now at £8,608.35m at the time of this report. The share price is in GBX. Mcap is measured in GBP. This article was written with the last trade for Centrica PLC being recorded at Wednesday, November 7, 2018 at 12:05:49 PM GMT with the stock price trading at 152.6 GBX.

 

Shares of Burberry Group plc with EPIC code: LON:BRBY has moved up 1.25% or 22.5 points during today’s session so far. Traders are a positive bunch during this period. The period high has peaked at 1844 and a low of 1805. The amount of shares exchanged has so far reached 409,780 with the average number of shares traded daily being 2,789,314. The 52 week high is 2338 about 544.5 points difference from the previous days close and putting the 52 week low at 1481.5 which is a difference of 312 points. Burberry Group plc has a 20 SMA of 1784.18 and a 50 day MA at 1975.47. The current market capitalisation is £7,468.34m at the time of this report. The share price is in GBX. Mcap is measured in GBP. This article was written with the last trade for Burberry Group plc being recorded at Wednesday, November 7, 2018 at 12:06:28 PM GMT with the stock price trading at 1816 GBX.

 

Shares of Associated British Foods plc found using EPIC: LON:ABF has moved up 3.34% or 82.28 points throughout today’s trading session so far. Traders have remained optimistic during the session. The period high has peaked at 2543 dropping as low as 2465.02. The total volume traded so far comes to 254,191 with the daily average number around 1,676,176. The stock 52 week high is 3300 some 840 points difference from the previous days close and putting the 52 week low at 2186 is a variance of 274 points. Associated British Foods plc now has a 20 SMA of 2378 and also a 50 day simple moving average now at 2325.98. The market capitalisation is now £20,126.58m at the time of this report. The share price is in Great British pence. Mcap is measured in GBP. This article was written with the last trade for Associated British Foods plc being recorded at Wednesday, November 7, 2018 at 12:06:05 PM GMT with the stock price trading at 2542.28 GBX.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:
AstraZeneca's Tagrisso gains EU approval for treating advanced NSCLC, showing significant efficacy in reducing disease progression in key trials.
GSK reports success in phase III trial of Zejula and Jemperli for advanced ovarian cancer, achieving significant progression-free survival improvement.
Centrica plc announces Kevin O'Byrne as new Chair and Jo Harlow as Senior Independent Director, with Scott Wheway stepping down today.
GSK's Jemperli receives FDA Breakthrough Therapy Designation for treating locally advanced dMMR/MSI-H rectal cancer, expediting crucial development.

Search

Search